mRNA-Based Therapeutics Summit

Memo

2020 marked a landmark year for mRNA-Based Therapies, and the dramatic success of mRNA-based vaccines for emergency use against COVID-19 was a triumph for a previously unproven mRNA technology. Now, the landscape of successful treatments seems limitless, and the future looks bright for mRNA therapies. With this, we are excited to announce the official release of the inaugural mRNA Based Therapeutics Summit! Uniting the world leaders developing mRNA therapeutics, we will will discuss learnings, challenges and future directions at the only summit dedicated to translation and manufacturing of your novel mRNA modality. From mRNA vaccine development for infectious disease and oncology, effective mRNA gene therapies and novel delivery strategies, we bring to you an all-inclusive platform dedicated to accelerating successful translation of mRNA into a transformative class of medicines. Date and Time: On Tuesday July 13, 2021 at 8:30 am (ends Thursday July 15, 2021 at 5:30 pm) Prices: Conference Only: USD 1999.00,Conference + Delivery and Manufacturing Focus Day: USD 2797.00 URLs: Tickets: https://go.evvnt.com/748182-1?pid=5569 Brochure: https://go.evvnt.com/748182-3?pid=5569 Speakers: Lori Panther, Vice President, Clinical Development, Infectious Diseases, Moderna, Inc, Jacob Becraft, Chief Scientific Officer and Co-Founder, Strand Therapeutics Inc, Daniel Griffith, Anderson Professor of Chemical Engineering, Institute for Medical Engineering and Science, Koch Institute for Integrative Cancer Research at MIT, Laura Sepp-Lorenzino, Chief Scientific Officer, Intellia Therapeutics, Andreas Kuhn, Senior Vice President RNA Biochemistry and Manufacturing, BioNTech GmbH, Russell Johnson, Local Head Basic Pharmaceutical Sciences, Drug Product, GSK Vaccines, Allison August, Vice President, Clinical Development, Infectious Diseases, Moderna, Inc, Norman Begg, Independent Vaccine Consultant, Former Chief Medical Officer, GSK Vaccines, Venkata R Krishnamurthy, Director and Senior Advisor, Eli Lilly and Company , Tasuku Kitada, Co-Founder, Director, President, and Head of R&D, Strand Therapeutics, Lusong Luo, Senior Vice President, External Innovation, BeiGene, Carsten Rudolph, Managing Director and Chief Scientific Officer, Ethris GmbH, Lior Zangi, Associate Professor, Icahn School of Medicine at Mount Sinai, Joseph Barberio, Director, mRNA Process Development, Strand Therapeutics Inc, Kristy Wood, Senior Director, Technical Operations, Intellia Therapeutics, Jay Sarkar, Co-founder and Chief Technology Officer, Turn Biotechnologies, Mouhannad Jumaa, Senior Vice President of Pharmaceutical Development, Turn Biotechnologies, Anthony Partridge, Senior Principal Scientist, MSD Singapore, Ali Miserez, Professor, Nanyang Technological University, Singapore, Shu-Bing Qian, Professor, Cornell University, Vittorio Sebastiano, Assistant Professor OBGyN, Stanford University, Gal Cafri, Immunotherapy and Genetic Engineering Group Leader, Sheba Medical Center, Pad Chivukula, Chief Scientific Officer and Chief Operating Officer, Arcturus Therapeutics, Yizhou Dong, Associate Professor, The Ohio State University , Nicolas Havelange, CMC Lead, CEPI, Pooja Tiwari, Associate Scientist, Emory School of Medicine , Jimmy Chu, Scientist II, mRNA Process Development, bluebird bio, James Sullivan, Senior Vice President Pulmonary Research, Translate Bio